Manipal Academy of Higher Education

Impressions@MAHE
Manipal College of Pharmaceutical Sciences,
Manipal Theses and Dissertations

MAHE Student Work

Winter 1-4-2019

Use of Surfactants for the treatment of Neonatal Respiratory
Distress Syndrome
Rajesh V Dr

Follow this and additional works at: https://impressions.manipal.edu/mcops
Part of the Pharmacy and Pharmaceutical Sciences Commons

USE OF SURFACTANTS IN THE TREATMENT OF
NEONATAL RESPIRATORY DISTRESS SYNDROME
A Project Report Submitted to
MANIPAL ACADEMY OF HIGHER EDUCATION

In partial fulfillment for the degree of Doctor of Pharmacy
(Pharm D)

Submitted By:
PAREETA KOTECHA
Reg. No: 140614015

RUPAL F. AROZA
Reg. No: 140614003

Pharm D 5th year
Department of Pharmacy Practice,
Manipal College of Pharmaceutical Sciences,
Manipal Academy of Higher Education,
Manipal.

APRIL 2019
Under the Guidance of:
Guide:
Dr. RAJESH V
Assistant professor,
Department of Pharmacy Practice,
Manipal College of Pharmaceutical sciences,
Manipal Academy of Higher Education
Dr. LESLIE EDWARD LEWIS
Head of Neonatology,
Department of Paediatrics, KMC,
Manipal Academy of Higher
Education

Co-guide

Dr. M.SURULIVEL RAJAN
Associate professor,
Department of Pharmacy Practice,
Manipal College of Pharmaceutical Sciences,
Manipal Academy of Higher Education

We hereby declare that the project entitled,
“Use of Surfactants for the treatment of Neonatal Respiratory Distress Syndrome” was
carried out under the guidance of Dr.Rajesh V, Department of Pharmacy Practice, Manipal
College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal and
co-guides Dr. Leslie Edward Lewis, Unit head Neonatology,KMC, Manipal Academy of
Higher Education and Dr. M.Surulivel Rajan,Associate professor , Department of
Pharmacy Practice, Manipal College of Pharmaceutical Sciences
The extent and source of information derived from the existing literature have been
indicated throughout the project work at appropriate places. The work is original and has
not been submitted in part or full for any diploma or degree purpose for this or any other
university.

Pareeta Kotecha
Reg No: 140614015

Rupal F. Aroza
Reg No: 140614003

This is to certify that this project report entitled “Use Of Surfactants in the treatment of
Neonatal Respiratory Distress Syndrome”, by Ms. Pareeta Kotecha, and Ms. Rupal F. Aroza
for the completion of 5th year PharmD comprises of the bonafide work done by them in
the Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences and
Kasturba Hospital, Manipal, under the guidance of, Dr. Rajesh V, Assistant professor,
Department of Pharmacy Practice, Manipal College of Pharmaceutical sciences and co-guides
Dr. Leslie Edward Lewis, Unit head Neonatology,KMC, Manipal Academy of Higher Education
and Dr. M.Surulivel Rajan,Associate professor , Department of Pharmacy Practice, Manipal
College of Pharmaceutical Sciences
I recommend this piece of work for acceptance for the partial fulfilment of the completion of
the 5th year Pharm D program of the Manipal Academy of Higher Education, Manipal for the
Academic year 2018-2019.
Dr. Rajesh V
Assistant professor,
Department of Pharmacy Practice,
Manipal College of Pharmaceutical sciences,
Manipal Academy of Higher Education
Manipal – 576104
Karnataka, India

Place: Manipal
Date:

This is to certify that this project report entitled “Use Of Surfactants in the treatment of
Neonatal Respiratory Distress Syndrome”, by Ms. Pareeta Kotecha, and Ms. Rupal F. Aroza
for the completion of 5th year PharmD comprises of the bonafide work done by them in
the Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences and
Kasturba Hospital, Manipal, under the guidance of, Dr. Rajesh V, Assistant professor,
Department of Pharmacy Practice, Manipal College of Pharmaceutical sciences and co-guides
Dr. Leslie Edward Lewis, Unit head Neonatology,KMC, Manipal Academy of Higher Education
and Dr. M.Surulivel Rajan,Associate professor , Department of Pharmacy Practice, Manipal
College of Pharmaceutical Sciences

I recommend this piece of work for acceptance for the partial fulfilment of the completion of
the 5th year Pharm D program of the Manipal Academy of Higher Education, Manipal for the
Academic year 2018-2019.

Dr. M.Surulivel Rajan
Associate professor,
Department of Pharmacy Practice,
Manipal College of Pharmaceutical sciences,
Manipal Academy of Higher Education
Manipal – 576104
Karnataka, India
Place: Manipal
Date:

This is to certify that this project report entitled “Use Of Surfactants in the treatment of
Neonatal Respiratory Distress Syndrome”, by Ms. Pareeta Kotecha, and Ms. Rupal F.
Aroza for the completion of 5th year PharmD comprises of the bonafide work done by
them in the Department of Pharmacy Practice, Manipal College of Pharmaceutical
Sciences and Kasturba Hospital, Manipal, under the guidance of, Dr. Rajesh V, Assistant
professor, Department of Pharmacy Practice, Manipal College of Pharmaceutical sciences and
co-guides Dr. Leslie Edward Lewis, Unit head Neonatology,KMC, Manipal Academy of
Higher Education and Dr. M.Surulivel Rajan, M.Pharm, Ph.D ,Associate professor ,
Department of Pharmacy Practice, Manipal College of Pharmaceutical sciences

I recommend this piece of work for acceptance for the partial fulfilment of the completion of
the 5th year Pharm D program of the Manipal Academy of Higher Education, Manipal for the
Academic year 2018-2019.
Dr.Leslie Edward Lewis
DNB Paediatrics
Head of Neonatology
Kasturba Medical College
Manipal Academy of Higher Education
Manipal – 576104
Karnataka, India

Place: Manipal
Date:

This is to certify that this project report entitled “Use Of Surfactants in the treatment of
Neonatal Respiratory Distress Syndrome”, by Ms. Pareeta Kotecha, and Ms. Rupal F.
Aroza for the completion of 5th year PharmD comprises of the bonafide work done by
them in the Department of Pharmacy Practice, Manipal College of Pharmaceutical
Sciences and Kasturba Hospital, Manipal, under the guidance of, Dr. Rajesh V, Assistant
professor ,Department of Pharmacy Practice, Manipal College of Pharmaceutical sciences and
co-guides Dr. Leslie Edward Lewis, Unit head Neonatology,KMC, Manipal Academy of
Higher Education and Dr. M.Surulivel Rajan, M.Pharm, Ph.D ,Associate professor ,
Department of Pharmacy Practice, Manipal College of Pharmaceutical sciences

I recommend this piece of work for acceptance for the partial fulfilment of the completion of
the 5th year Pharm D program of the Manipal Academy of Higher Education, Manipal for the
Academic year 2018-2019.
Dr. Mahadev Rao
M.Pharm, PhD
Professor and Head
Department of Pharmacy Practice
Manipal College of Pharmaceutical Sciences
Manipal Academy of Higher Education
Manipal – 576104
Karnataka, India

Place: Manipal
Date:

This is to certify that this project report entitled “Use Of Surfactants in the treatment of
Neonatal Respiratory Distress Syndrome”, by Ms. Pareeta Kotecha, and Ms. Rupal F.
Aroza for the completion of 5th year PharmD comprises of the bonafide work done by
them in the Department of Pharmacy Practice, Manipal College of Pharmaceutical
Sciences and Kasturba Hospital, Manipal, under the guidance of, Dr. Rajesh V, Assistant
professor,Department of Pharmacy Practice, Manipal College of Pharmaceutical sciences and
co-guides Dr. Leslie Edward Lewis, Unit head Neonatology,KMC, Manipal Academy of
Higher Education and Dr. M.Surulivel Rajan, M.Pharm, Ph.D ,Associate professor ,
Department of Pharmacy Practice, Manipal College of Pharmaceutical sciences

I recommend this piece of work for acceptance for the partial fulfilment of the completion of
the 5th year Pharm D program of the Manipal Academy of Higher Education, Manipal for the
Academic year 2018-2019.

Dr. C. Mallikarjuna Rao
M.Pharm, PhD
Principal
Manipal College of Pharmaceutical Sciences
Manipal Academy of Higher Education
Manipal – 576104
Karnataka, India

Place: Manipal
Date:

Acknowledgement
“In the name of God, the Almighty, the most Generous and Merciful”

We express our utmost gratefulness to the almighty for the blessing throughout this study.
We are extremely thankful to our parents, teachers and friends for giving us the opportunity
to carry ourselves forward in the path of dream and for their unflagging love, care, attention,
concern and support throughout our life.
We humbly owe gratitude and sincere regards to our respected guide Dr. Rajesh V, Assistant
professor, Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences and
our co-guide Dr. M.Surulivel Rajan , Associate professor, Department of Pharmacy Practice,
Manipal College of Pharmaceutical Sciences for their valuable guidance, encouragement,
untiring patience and support laid by them during all stages of our work. Their encouragement
and fruitful suggestions have enabled to make our work worthy of presentation.
We extend our sincere and heartfelt thanks to Dr. Leslie Edward Lewis, for his endless support
and cooperation.
We would like to thank our departmental non-teaching staff Mrs. Ashalatha and Mr. Abhilash
for their endless support and cooperation.
Special thanks to the staff of IP MRD, Kasturba Hospital, Manipal who have directly or
indirectly made us capable for successful completion of the study.

LIST OF ABBREVIATIONS
RDS

Respiratory distress syndrome

DPPC

Dipalmitoylphosphatidylcholine

PROM

Preterm rupture of the membrane

IDM

Infant of Diabetic mother

BPD

Bronchopulmonary dysplasia

NCPAP

Nasal continuous positive airway pressure

ABG

Arterial blood gases

PCo2

Partial pressure of carbon dioxide

PO2

Partial pressure of oxygen

HCO3

Bicarbonate

BE

Base excess

TABLE OF CONTENTS
SL. No

CONTENTS

PAGE No.

1

ABSTRACT

2

2

INTRODUCTION

4

3

AIMS & OBJECTIVES

8

4

METHODOLOGY

10

5

RESULTS

12

6

DISCUSSION

15

7

LIMITATIONS

42

8

CONCLUSIONS

51

9

FUTURE DIRECTIONS

53

10

REFERENCES

55

11

APPENDICES

60

LIST OF TABLES
TABLE No.

TITLE

PAGE No.

1

Demographic characteristics of neonates with RDS

15

2

General characteristics and frequency before intervention

20

3

Comparison between the effects of three types of surfactants
on different variables among neonates receiving surfactant
after intervention
Effects of different surfactants on different variables among
neonates receiving surfactants according to their gestational
age- Less than or equal to 32 weeks
Effects of different surfactants on different variables among
neonates receiving surfactants according to their gestational
age- More than 32 weeks
Two-by-two comparison of the effects of Survanta and
Curosurf on Several variables among neonates after
intervention
Two-by-two comparison of the effects of Survanta and Neosurf
on Several variables among neonates after intervention
Two-by-two comparison of the effects of Curosurf and Neosurf
on Several variables among neonates after intervention
Comparison of pre and post pH values of surfactants used in

22

4

5

6

7
8
9

24

26

27

28
29
30

the treatment of RDS
10
11
12
13
14
15
16

Comparison of pre and post pco2 values of surfactants used in
the treatment of RDS
Comparison of pre and post pO2 values of surfactants used in
the treatment of RDS
Comparison of pre and post HCO3 values of surfactants used
in the treatment of RDS
Comparison of pre and post Base excess values of surfactants
used in the treatment of RDS
Severity of RDS with respect to mothers comorbidities during
the gestation period
Severity of RDS with respect to medications taken by the
mothers during the gestation period
Severity of RDS with respect to APGAR score of neonate

30
30
31
31
32
33
35

17

36

18

Severity of RDS with respect to multiple pregnancy,Preterm
rupture of membrane and mode of delivery
Severity of RDS with respect to gestational age of the neonate

19

Severity of RDS with respect to gender of the neonate

37

20

Severity of RDS with respect to comorbidities of the neonate

38

21

Severity of RDS with respect to use of antenatal steroids

40

22

Relation between use of antenatal steroids and death in
neonates
Relation between antenatal use of Dexamethasone and death
in neonates
Relation between antenatal use of Betamethasone and death in
neonates

40

23
24

37

41
41

LIST OF FIGURES

FIGURE No.

TITLE

PAGE No.

1

Incidence of RDS over the years

18

2

Distribution of neonates according to RDS
severity
Distribution of neonates according to surfactant
treatment
Distribution of neonates as per the type of
surfactant given

19

3
4

19
20

LIST OF APPENDICES
APPENDIX No.

TITLE

PAGE No.

I

IEC APPROVAL CERTIFICATE

60

II

CASE REPORT FORM

61

III

TURNITIN PLAGIARISM REPORT

63

ABSTRACT

1

ABSTRACT
Background: Respiratory Distress Syndrome (RDS) is breathing disorder that affects the
newborns especially preterm neonates, extremely low birth weight and very low birth weight
neonates. This is due to lack of surfactant production in the lungs of a premature baby.
Surfactant therapy and oxygen support improves the condition of the neonate with RDS. Use
antenatal steroid prevents the occurrence of RDS/reduces the severity of RDS. This study is
necessary to assess which surfactant is better, risk factors associated with RDS and
comorbidities of neonates present along with RDS.
Objectives: The objectives of the studies are to compare the surfactants used in the treatment
of respiratory distress syndrome in neonates, assessing risk factors associated with RDS, to
evaluate correlation of RDS with other comorbid conditions, to evaluate use of steroids in
pregnant mothers and its effects on Neonatal Respiratory Distress syndrome.
Methodology: A retrospective study was conducted over one year where 610 patients were
enrolled based on inclusion and exclusion criteria of the study. Their relevant demographics,
etiology, treatment patterns were noted. IBM SPSS version 20 was used for statistical
analysis.
Results: A total of 610 patients diagnosed with RDS were included in the study. The mean
age of the study population was found to be 31.80±3.161 weeks and the mean birth weight
was found to be 1647.28±717.31 grams. The incidence of RDS was higher in males
(58.03%), extremely low birth weight and low birth weight babies 8.85% and 47.04%
respectively, caesarean section delivery 77.04% along with other risk factors such as
preeclampsia, IDM, PROM and presence of complications of prematurity associated with
RDS. It was found that Curosurf group required less NCPAP as compared to Survanta and
Neosurf (p=0.010). Curosurf and Survanta significantly reduced pCO2 values (p=0.002 and
p=0.03 respectively). There was a significant association between APGAR score and severity
of RDS at 1 minute and 5 minutes (p=0.00) for both 1 minute and 5 minutes and Gestational
age and RDS severity (p=0.00). There was a significant association between the use of
antental steroids and reduction in neonatal mortality (p= 0.001).
Conclusion: Curosurf was found to be better of the three surfactants and the risk of RDS
reduced with improving APGAR scores, gestational age and birth weight. Other risk factors
contributing towards RDS in neonates were found to be preeclampsia, PROM, IDM and
hypothyroidism. Use of antenatal steroid reduced neonatal morbidity associated with RDS.
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INTRODUCTION
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Respiratory Distress Syndrome (RDS) can be defined as a breathing disorder that affects
newborns. This disorder is more common in premature infants whereas in full term infants
RDS occurs rarely. (National Institute of Health)
According to the Indian National Neonatal Perinatal Database, incidence of RDS was found
to be 1.2%, and an RDS-specific mortality rate was found to be 13.5%, in a population in
which 31.4% of infants were born at low birth weight and 14.5% were preterm. (National
Neonatal Perinatal Database, 2005)

Preterm neonates have highest incidence of RDS followed by post term and term neonates.
Transient tachypnea of the newborn is the most common cause of RDS in neonates followed
by infections, meconium aspiration syndrome, hyaline membrane disease and birth asphyxia.
Transient tachypnea of newborn was found to be the most common cause among both term
and preterm neonates whereas Hyaline membrane disease was mostly seen in preterm
neonates, whereas Meconium aspiration syndrome in term and post term babies. (Kumar and
Vishnu Bhat, 1996) Among premature babies, the risk of developing RDS was found to be
increased among Caucasian race, male sex, and an older sibling with RDS, caesarean
delivery, perinatal asphyxia, and maternal diabetes. (Goldenberg et al., 2008).

Lungs of premature infants do not have the ability to make enough surfactant. In the insides
of the lungs, surfactant acts like a liquid coat. Which helps keep them open so that infants can
breathe in air once they are born. (National Institute of Health). Without enough surfactant,
the lungs tend to collapse and the infant has to work hard to breathe. The infant might not be
able to breathe in enough oxygen to support the body's organs. If proper treatment is not
provided, lack of oxygen can damage the baby's brain and other organs, this in turn leads to
increased levels of carbon dioxide in the blood. Most babies who develop RDS exhibit signs
of breathing problems and a lack of oxygen at birth or within the first few hours that follow.
(National Institute of Health)

The signs and symptoms exhibited by a neonate which includes, respiratory difficulty at birth
that progressively worsens, cyanosis, flaring of the nostrils, tachyapnea, grunting sounds
while breathing, chest retractions. (National Institute of Health)

Antenatal steroid treatment has emerged to be the most effective intervention for the
prevention of RDS in neonates for women who are at risk of preterm delivery, which in turn
4

helps in reducing early neonatal mortality and morbidity. Most glucocorticoid hormones,
whether natural or artificial, are capable of crossing the placenta which trigger the
maturational process leading to the production and release of surfactant into the alveoli of the
foetal lung (Mwansa – Kambafwile et al., 2010)

The National Institutes of Health (NIH) Consensus Development Conference recommended
treatment regimens with either two doses of 12 mg of betamethasone that can be given
intramuscularly 24 hours apart or four doses of 6 mg of dexamethasone given intramuscularly
12 hours apart between 24 and 34 weeks of gestation in pregnancies who are at risk for
preterm delivery. It is well established that a complete course of antenatal corticosteroids is
better than an incomplete course in decreasing the risk of RDS. (Chen et al., 2005).

When optimal prenatal care is provided, the best approach to treat RDS, according to several
recent trials, (Subramanian, Ho and Davis, 2016) consists in providing continuous positive
airway pressure from the first minutes of life using short binasal prongs, (De Paoli et al.,
2008) which is then followed by early selective surfactant administration for babies with
worsening of oxygenation and/or increasing work of breathing. Both European and American
guidelines advise in favour of this strategy, which reduces mortality and bronchopulmonary
dysplasia (BPD). Mechanical ventilation is one of the most common therapies in the neonatal
intensive care unit (NICU). (Al Hazzani et al., 2017)

Currently available surfactants are animal-derived preparations. They resulted to be superior
to older synthetic (protein-free) surfactants, as the proteins improve surfactant activity,
stabilizing the film at the air/liquid interface. (Aedell, Pfister and Soll, 2015). Secretion into
the alveolus by type II epithelial cells will lead to synthesis of surfactant lipids and proteins, a
process that is developmentally regulated and influenced by hormones like glucocorticoids
Jobe and Ikegami (2000). (Whitsett and Stahlman, 2010). Surfactant storing Lamellar bodies
appear at 22 to 24 weeks. Surfactant is a mixture of lipids and apoproteins, the main
constituents include dipalmitoylphosphatidyl choline(DPPC), phosphatidylglycerol(PG) and
apoproteins A, B, C and D. Surfactant maintains stability when breathing out, to prevent
collapse of the alveoli. (Roberts et al, 2017).

With increasing gestational age the surfactant production will increase in the normal neonate.
Causes of RDS are the lack of lung maturity and surfactant deficiency. Various factors can
5

inactivate surfactant such as presence of meconium in the airways, pulmonary edema,
alveolar capillary leak and pulmonary hemorrhage. Decrease in the activity of a surfactant
may result in alveolar collapse, atelectasis, ventilation-perfusion abnormalities, decreased
lung compliance, resulting in a decreased ventilation and pulmonary hypertension leading to
respiratory failure. Surfactant enhances the clearance of lung liquid and maintaines lung
volume. Surfactant replacement decreases the incidence of air leak and mortality that
accompany RDS. ( Whitsett and Stahlman, 2010)

Commonly used surfactants used for treatment of RDS are; [13]; (Tridente, De Martino and
De Luca,2019)
Biochemical

Trade

Surfacta

Source of

Total

Name

Name

nt type

extract

Beractant

Survanta

Natural

Bovine,

Main PL

SP-B

SP-C

PL

(mg/ml

(mg/ml)

(mg/ml)

)

25

DPPC

minced

Curosurf

Natural

alpha

Porcine

27

extract

DPPC

minced

Neosurf

Natural

Bovine

0.17

0.49

0.45

0.9

PS 4%

42%

lungs
Bovine lipid

0.3

70%

lung
Poractant

0.03

PG 11%
80

lung lavage

surfactant

DPPC
46%
PE 6%

(BLES)
DPPC-dipalmitoylphosphatidylcholine; SP-B -Surfactant protein B; SP-C-Surfactant protein C;
PL-phospholipids; PS-phosphatidylserine; PG-phosphatidylglycerol;
PE-bovine brain phosphatidylethanolamine

In a Cochrane meta-analysis surfactants were subdivided according to the extraction method
(lung lavage or minced lung extract) and into bovine and porcine-derived. The result showed
that porcine minced surfactant had more favourable outcomes than those treated with bovine
minced lung surfactant. No significant difference between bovine lung lavage and bovine
minced lung-derived surfactant were found. (Singh et al., 2015).
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NEED FOR STUDY
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Need for study:

Respiratory distress syndrome (RDS) is the most common cause of respiratory failure and
morbidity and mortality in premature infants. In developing countries, RDS mortality rate and
percentage of complications still remain high in comparison to the developed countries,
despite facilities for respiratory care of newborn RDS infants requiring Mechanical
Ventilation (MV) had survival rate of 25% in the newborns with birth weight <1000 grams
up to 53% in those with birth weight >2500 grams. There is limited data about causes of high
mortality rate in infants with RDS from developing countries. Outcome of neonatal RDS can
be improved by improvement of perinatal care and diminution of risk factors, use of a
surfactant as well as antenatal steroids. (Fidanovski et al., 2005)

8

AIM & OBJECTIVES
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Aim:


To assess, understand and compare the role and use of surfactants used in the prevention
and treatment of Respiratory Distress Syndrome in neonates, to interpret the effectiveness
and use antenatal steroids in reducing the severity of RDS in neonates, to assess the risk
factors and comorbidities associated with Respiratory Distress Syndrome.

Objectives:


Comparison of surfactants used in the treatment of Respiratory Distress Syndrome in
neonates.



Assessing risk factors associated with Respiratory Distress Syndrome



To evaluate use of steroids in pregnant mothers and its effects on Neonatal Respiratory
Distress syndrome.

10

METHODOLOGY
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Methodology:

Study site: A study conducted in Kasturba Hospital, Manipal

Study design: Single Centered Retrospective Cross sectional Study.

Study period: One year from the date of approval by the Ethics Committee.

Sample size: 610 patients

Ethics Approval
The Institutional Ethics Committee approval was obtained prior to outset of the study
(Approval number: 399/2018) (Appendix 1).

Study Criteria
Inclusion criteria: Patients admitted under ICD code P22.0 from the year 2012-2017.
Exclusion criteria: Incomplete data; i.e. when more than 50 per cent of data per patient is
unavailable, the data is excluded.

Data source:
The study population broadly represents South Indian population. All the necessary and
relevant data were obtained from the medical records of patients diagnosed with Respiratory
distress syndrome during the study period.

Materials used: Case Record Form (CRF).

Operation modality:
Patient identification and enrolment: Cases were identified from the MRD by International
Classification of Diseases (ICD) code for Neonatal Respiratory Distress Syndrome ICD P
22.0 from the year 2013 to 2017

Collection of data: Patient medical records of all Neonatal Respiratory Distress Syndrome
were reviewed and all the required information like demographic details, treatment pattern
and outcome of each patient was entered in the CRF.
12

Statistical Analysis:
For data analysis, Statistical Package for Social Sciences (SPSS) version 20.0 was used.
Categorical data was presented as frequencies with percentages. Continuous data was
presented as mean ± SD. For the primary objective i.e. Comparison of surfactants used in the
treatment of Respiratory Distress Syndrome in Neonates One-way ANOVA and cross tabs
with Chi-square were used. Whereas for other objectives i.e assessing the risk factors,
comorbidities and use of antenatal steroids various tests such as descriptives with frequency,
crosstabs with Chi square and One-way ANOVA were used. A p-value of less than 0.05 was
found to be statistically significant.
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RESULTS
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Patient Characteristics:
A total of 610 patients diagnosed with RDS were included in the study. The mean age of the
study population was found to be 31.80±3.161 weeks and the mean birth weight was found to
be 1647.28±717.31 grams.
The demographic characteristics of these patients are depicted in the table below:

Table 1: Demographic characteristics of neonates with RDS
Characteristics

Number of Neonates n (%)

Gender
 Male
 Female
Gestational age
 Extremely preterm (<28 weeks)
 Very preterm (28 – 32 weeks)
 Moderate to late preterm
 Term
 Not available
Birth weight
 Extremely low birth weight (<1000 g)
 Very low birth weight (<1500 g)
 Low birth weight (<2500 g)
 Normal (2500 – 4500 g )
 Macrosomia (>4500 g)
 Not Available
Mode of delivery
 Vaginal
 Caesarean
 Not available
Multiple pregnancy
 Yes
 No
Preterm rupture of the membrane
 Yes
 No
Preeclampsia
 Yes
 No
Infant of Diabetic mother
 Yes
 No

15

354 (58.03)
256 (41.96)
54 (8.85)
287 (47.04)
240 (39.34)
16 (2.62)
13 (2.13)
106 (17.37)
186 (30.49)
241 (39.50)
67 (10.98)
2 (0.32)
8 (1.31)
133 (21.80)
470 (77.04)
7 (1.14)
112 (18.36)
498 (81.63)
113 (18.52)
497 (81.47)
121 (19.83)
489 (80.16)
44 (7.21)
566 (92.78)

Table 1: Demographic characteristics of neonates with RDS (contd.)
Antenatal steroid
 No steroid
 Betamethasone
 Dexamethasone
 Both
 Steroid given but details not known
 Not available

98 (16.06)
32 (5.24)
29 (4.75)
1 (0.16)
202 (33.11)
248 (40.65)

Pneumothorax
 Yes
 No

16 (2.62)
594 (97.37)

Retinopathy
 Yes
 No
Patent ductus arteriosus
 Yes
 No
Bronchopulmonary dysplasia
 Yes
 No
Intracranial haemorrhage
 Yes
 No
Pulmonary haemorrhage
 Yes
 No
Ventilator therapy
 Yes
 No
NCPAP support
 Yes
 No
NCPAP support + Ventilator therapy
 Yes
 No
Death
 Yes
 No
 Not available

89 (14.59)
521 (85.40)
42 (6.88)
568 (93.11)
2 (0.32)
608 (99.67)
6 (0.98)
604 (99.01)
8 (1.31)
602 (98.68)
99 (16.22)
511 (83.77)
238 (39.01)
372 (60.98)
235 (38.52)
375 (61.47)
58 (9.50)
551 (90.32)
1 (0.16)

According to the table depicted above (Table 1), frequencies of various characteristics that
are associated among neonates who were diagnosed with RDS are as follows; out of 610
neonates, 354 (58.03%) neonates were male, 256 (41.96%) neonates were females, 54
(8.85%) neonates were Extremely preterm (<28 weeks), 287 (47.04%) of neonates were Very
preterm (28 – 32 weeks), 240 (39.34%) neonates were Moderate to late preterm,16 (2.62%)
16

neonates were born within the appropriate gestational age and were term babies. With respect
to birth weight of neonates; 106 (17.37%) neonates had extremely low birth weight (<1000
g), 186 (30.49%) neonates had very low birth weight (<1500 g), 241 (39.50%) neonates had
low birth weight (<2500 g), 67 (10.98%) neonates had normal birth weight (2500 – 4500 g),
2 (0.32%) neonates were found to be Macrosomial (>4500 g). With regard to mode of
delivery; 133 (21.80%) neonates were delivered through vaginal delivery and 470 (77.04%)
of neonates were delivered by caesarean. 112 (18.36%) of mothers had multiple pregnancies,
113 (18.52%) mothers had preterm rupture of the membrane, 121 (19.83%) mothers had
preeclampsia, and 44 (7.21%) neonates were found to be infants of Diabetic mothers. With
respect to the mother receiving antenatal steroid; 98 (16.06%) neonates did not receive
steroids, 32 (5.24%) mothers received betamethasone, 29 (4.75%) mothers received
dexamethasone, 1(0.16%) mother received both betamethasone and dexamethasone, 202
(33.11%) mothers had received steroid but details of which steroid that was received were not
known. 16 (2.62%) neonates had pneumothorax, 89 (14.59%) neonates had retinopathy, 42
(6.88%) neonates had patent ductus arteriosus, 2 (0.32%) had bronchopulmonary dysplasia, 6
(0.98%) neonates had intracranial haemorrhage, 8 (1.31%) neonates had pulmonary
haemorrhage. 99 (16.22%) neonates received ventilator therapy, 238 (39.01%) had received
NCPAP support and 235 (38.52%) neonates had received both NCPAP support and ventilator
support. The mortality was found to be 9.50% (58 of 610).

Incidence of RDS over the years:
The incidence of RDS was found to be the highest in the year 2015 followed by 2016,2017
and 2014 respectively.
2013* had more number of cases than depicted but, only 20 were accessible. (Figure 1)
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Figure 1: Incidence of RDS over the years

Distribution of Neonates According to RDS Severity
Maximum number of neonates were under the category Mild 240 (39.34) followed by Severe
160 (26.22), Moderate 156 (25.5), Severity not specified 28 (4.59) and Severity not available
26(4.26) respectively. (Figure 2)
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Figure 2: distribution of neonates according to RDS severity

Comparison of Surfactants used in the Treatment of Respiratory Distress Syndrome in
Neonates

Out of 610 patients a total of 192 patients were given surfactant.(Figure 3) Out of which
136(70.83) patients were given Survanta followed by Curosurf (21.87), Neosurf (4.68) and
one neonate was given both Survanta and Neosurf (0.52) and unknown surfactant 4(2.08).
(Figure 4)
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Figure 3: Distribution of neonates according to surfactant treatment
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Figure 4: Distribution of neonates as per the type of surfactant given
Table 2: General Characteristics and frequency before intervention
Variables

Gender
 Male
 Female
Gestational age
(weeks)
 ≤32
 >32
Birth weight (grams)
 <1,500
 1,500-2,500
 >2,500
Mode of Delivery
 Caesarean
 Vaginal
Pneumothorax
 Yes
 No
Sepsis
 Yes
 No
Patent Ductus
Arteriosus
 Yes
 No

Survanta

Type of Surfactant
Curosurf
Neosurf

78 (69.64)
58 (73.4)

24 (21.42)
18 (22.78)

7 (6.25)
2 (2.53)

Not
known
3 (2.67)
1 (1.26)

p
Value

Total (%)

0.587

112 (58.63)
79 (41.36)

0.017

163(87.16)
24(12.83)

0.012

155 (81.15)
31 (16.23)
5 (2.61)

0.881

146 (76.84)
44 (23.15)

110(67.48)
23(95.83)

41 (25.15)
0

9(5.52)
0

3(1.84)
1(4.16)

103 (66.45)
29 (93.5)
4 (80)

41 (26.45)
0
1 (20)

9 (5.80)
0
0

2 (1.29)
2 (6.45)
0

105 (71.91)
30 (68.18)

30 (20.54)
12 (27.27)

7 (4.79)
2 (4.54)

4 (2.73)
0

6 (100)
130 (70.27)

0
42 (22.70)

0
9 (4.86)

0
4 (2.16)

0.474

6 (3.14)
185 (96.85)

31 (58.49)
105 (76.08)

18 (33.96)
24 (17.39)

3 (5.66)
6 (4.34)

1 (1.88)
3 (2.17)

0.086

53 (27.74)
138 (72.25)

15 (78.94)
121 (70.34)

3 (15.78)
39 (22.67)

1 (5.26)
8 (4.65)

0
4 (2.32)
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0.801

19 (9.94)
172 (90.05)

Table 2: General Characteristics and frequency before intervention(contd.)
Retinopathy
 Yes
 No
Bronchopulmonary
Dysplasia
 Yes
 No
Intracranial
Hemorrhage
 Yes
 No
Pulmonary
Hemorrhage
 Yes
 No
Preeclampsia
 Yes
 No
Preterm Rupture of
Membrane
 Yes
 No
Infant of Diabetic
Mother
 Yes
 No

32 (74.41)
104 (70.27)

6 (13.95)
36 (24.32)

3 (6.97)
6 (4.05)

2 (4.65)
2 (1.35)

136 (71.20)

42 (21.98)

9 (4.71)

4 (2.09)

4 (100)
132 (70.58)

0
42 (22.45)

0
9 (4.81)

0
4 (2.13)

4 (80)
132 (70.96)

0
42 (22.58)

0
9 (4.83)

1 (20)
3 (1.61)

5 (2.61)
186 (97.38)

28 (62.22)
108 (73.97)

15 (33.33)
27 (18.49)

1 (2.22)
8 (5.47)

1 (2.22)
3 (2.05)

45 (23.56)
146 (76.43)

31(73.80)
105(70.46)

8(19.04)
34(22.81)

2(4.76)
7(4.69)

1(2.38)
3(2.01)

10 (76.92)
126 (70.78)

2 (15.38)
40 (22.47)

1 (7.69)
8 (4.49)

0
4 (2.24)

0.256
-

43 (22.51)
148 (77.48)

191 (100)

0.648

4 (2.09)
187 (97.90)

0.026

0.180

0.963

0.826

42 (21.9)
149 (78.01)

13 (6.80)
178 (93.19)

191 of 610 neonates were given Surfactant therapy. The neonates were divided based on the
surfactant given and further subdivided on various characteristics such as gender
(male/female), gestational age (≤32/>32 weeks) , birth weight (<1,500gm /1,500-2,500gm/
>2,500gm), mode of delivery (vaginal/caesarean), pneumothorax, sepsis, patent ductus
arteriosus, retinopathy, bronchopulmonary dysplasia, intracranial hemorrhage, pulmonary
hemorrhage, preeclampsia, preterm rupture of the membrane, infant of diabetic mother and
death.

Among those variables, the following were found to be statistically significant;
Gestational age (≤32/>32 weeks) (p value=0.017) which signifies there is a difference in the
usage of surfactants between the two groups. Surfactants were used more in ≤32 weeks
Survanta 110 (67.8), Curosurf 41 (21.15), Neosurf 9 (5.52) and surfactant not known 1 (1.84)
whereas in >32 weeks group the use of surfactants was as follows; Survanta 23 (95.83) and
surfactant not known 1 (4.16).
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Birth weight (p value=0.012) which signifies there is a difference in the usage of surfactants
between the three groups. In neonates with weight <1,500 gm the surfactant use was more i.e.
Survanta 103 (66.45), Curosurf 41 (26.45), Neosurf 9 (5.80) and surfactant not known 2
(1.29). Survanta 29 (93.5) was used in neonates with weight 1,500gm-2,500gm of body
weight. Curosurf and Neosurf were not given in this group, where as surfactant not known in
2 (6.45) cases. In neonates with weight >2,500gm the surfactants use were Survanta 4 (80),
Curosurf 1 (20) and Neosurf was not given in this group.
Pulmonary hemorrhage (p value=0.026) the difference between the groups for the incidence
rate of pulmonary hemorrhage was statistically significant.

Table 3: Comparison between the effects of the three types of surfactants on different
variables among neonates receiving surfactant after intervention
Variable

Duration of hospital stay

Type of Surfactant

p Value

Survanta

Curosurf

Neosurf

33.24±25.187

33.69±25.220

29.33±21.541

0.891

1306.50±659.63

1080.23±409.58

1105.55±241.31

0.081

29.77±2.820

28.95±1.85

29.11±1.83

0.189

13.19±13.894

15.90±15.771

12.22±15.015

0.537

1.06±0.266

1.12±0.395

1±0.00

0.394

(days) (mean±SD)
Birth weight (g)
( mean±SD)
Gestational age (weeks)
(mean±SD)
Ventilation time (days)
(mean±SD)
Number of Surfactant
injections (mean±SD)
Pneumothorax


Yes

6

0

0



No

130

42

9

0.313

Patent ductus arteriosus


Yes

15(78.94)

3(15.78)

1(5.26)



No

121(72.02)

39(23.21)

8(1.19)

22

0.763

Table 3: Comparison between the effects of the three types of surfactants on different variables
among neonates receiving surfactant after intervention (contd.)
-

BPD


Yes

-

-

-



No

136(72.72)

42(22.45)

9(4.81)

Intracranial haemorrhage


Yes

4(100)

0

0



No

132(72.13)

42(22.95)

9(4.91)

0.465

Pulmonary haemorrhage


Yes

4(100)

0

0



No

132(72.13)

42(22.95)

9(4.91)

0.465

Retinopathy


Yes

32(78.04)

6(14.63)

3(7.31)



No

104(71.23)

36(24.65)

6(4.10)

0.313

Ventilator therapy


Yes

21(63.63)

12(27.90)

0



No

115(74.67)

30(19.48)

9(6.08)

0.054

NCPAP support


Yes

9(64.28)

2(14.28)

3(21.42)



No

127(73.41)

40(23.12)

6(3.46)

0.010

NCPAP support and
Ventilator therapy


Yes

104(75.36)

28(20.28)

6(4.34)



No

32(65.30)

14(26.92)

3(6.12)

0.398

A total of 191 neonates were given surfactant therapy. Neonates who were given surfactant
but the name was not known were excluded (4). 187 neonates were then assessed based on
their effects on different variables.
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p value of 0.010 was found for NCPAP support which indicates that there is a significant
difference in the number of neonates requiring NCPAP support. Curosurf group had the least
number of neonates (2) who required NCPAP support after intervention.

There were no statistically significant differences between neonates treated with
Survanta/Curosurf or Neosurf in terms of other factors mentioned in the table.

In the next section, the neonates whose gestational age was not mentioned and who were
given a surfactant but it was not known which were excluded. (A total of 8 neonates were
excluded from a total of 191)

Table 4: Effects of different surfactants on various variables among neonates receiving
surfactant according to their gestational age- less than or equal to 32 weeks
Variables
Duration of hospital
stay (days) (mean±SD)
Birth weight (g)
(mean±SD)
Gestational age
(weeks) (mean±SD)
Ventilation time (days)
(mean±SD)
Sex




Male
Female

Pneumothorax
 Yes
 No
Patent ductus
arteriosus
 Yes
 No
BPD
 Yes
 No

Survanta
37.08±26.007
1172.681±576.400

Type of Surfactant
Curosurf
34.24±25.273

p value
Neosurf
29.33±21.541

1027.317±226.680 1105.555±241.317

0.608
0.278

28.854±2.106

28.9512±1.856

29.111±1.833

0.916

14.45±14.86

16.24±15.81

12.22±15.01

0.708

63 (67.02)
47 (71.21)

24 (25.53)
17 (25.75)

7 (7.44)
2 (3.03)

0.486

2 (100)
108 (68.35)

0
41 (25.94)

0
9 (5.69)

0.631

7 (63.63)
103 (69.12)

3 (27.27)
38 (25.50)

1 (9.09)
8 (5.36)

0.857

110 (68.75)

41 (25.62)

9 (5.62)

-
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Table 4: Effects of different surfactants on various variables among neonates receiving
surfactant according to their gestational age- less than or equal to 32 weeks (contd.)

Intracranial
haemorrhage
 Yes
 No
Pulmonary
haemorrhage
 Yes
 No
Retinopathy
 Yes
 No
Ventilator therapy
 Yes
 No
NCPAP support
 Yes
 No
NCPAP support and
Ventilator therapy
 Yes
 No
Death
 Yes
 No

0.394
4 (100)
106 (67.94)

0
41 (26.28)

0
9 (5.76)

3 (100)
107 (68.15)

0
41 (26.11)

0
9 (5.73)

31 (77.5)
79 (65.83)

6 (15)
35 (29.16)

3 (7.5)
6 (5)

13(54.16)
97(71.32)

11(45.83)
30 (22.05)

0
9(6.61)

0.031

7 (58.33)
103 (69.59)

2(16.66)
39(26.35)

3(25)
6(4.05)

0.010

88(72.13)
22(57.89)

28 (22.95)
13 (34.21)

6 (4.91)
3 (7.89)

0.254

19 (61.29)
91 (70.54)

10 (32.25)
31 (24.03)

2 (6.45)
7 (5.42)

0.601

0.499

0.194

The p values were calculated in the age group of ≤32 weeks a total of 160 neonates were
present in this category. Neonates whose age and the name of surfactant was not available
were excluded.
p value of 0.010 was found for NCPAP support which indicates that there is a significant
difference in the number of neonates requiring NCPAP support. Curosurf group had the least
number of neonates; 2 (16.66) who required NCPAP support after intervention as compared
to Survanta 7 (58.33) and Neosurf 3 (25).
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Table 5: Effects of different surfactants on various variables among neonates receiving
surfactant according to their gestational age - more than 32 weeks

VARIABLE
Duration of hospital
stay(days) (mean±SD)
Birth weight (g) ( mean±SD)
Gestational age (weeks)
(mean±SD)
Ventilation time (days)
(mean±SD)
Sex
 Male
 Female
Pneumothorax
 Yes
 No
Patent ductus arteriosus
 Yes
 No
BPD
 Yes
 No
Intracranial haemorrhage
 Yes
 No
Pulmonary haemorrhage
 Yes
 No
Retinopathy
 Yes
 No
Ventilator therapy
 Yes
 No
NCPAP support
 Yes
 No
NCPAP support and
Ventilator therapy
 Yes
 No
Death
 Yes

TYPE OF SURFACTANT
Survanta
Curosurf
Neosurf
17.48±12.15
233.74±164.99

-

-

34±1.154

-

-

p Value
-

7.78±6.755

-

-

13
10

-

-

-

4
19

-

-

-

8
15

-

-

23

-

-

23

-

-

23

-

-

1
22

-

-

-

-

-

6
17

-

-

2
21

-

-

15
8

-

-

3

-

-

-
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No

-

-

In the age group of >32 weeks only Survanta was used and therefore p value could not be
calculated.
Table 6: Two-by-Two Comparison of the Effects of Survanta and Curosurf on Several
Variables among Neonates after Intervention
Variable
Pneumothorax
 Yes
 No
Patent ductus arteriosus
 Yes
 No
BPD
 Yes
 No
Intracranial haemorrhage
 Yes
 No
Pulmonary haemorrhage
 Yes
 No
Retinopathy
 Yes
 No
Ventilator therapy
 Yes
 No
NCPAP support
 Yes
 No
NCPAP support and
Ventilator therapy
 Yes
 No

Type of surfactant

p Value

Survanta

Curosurf

6 (100)
130 (75.58)

0
42 (24.4)

0.166

15 (83.33)
121 (75.62)

3 (16.66)
39 (24.37)

0.465

136 (76.4)

42 (24.41)

-

4 (100)
132 (75.86)

0
42 (24.13)

0.261

4 (100)
132 (75.86)

0
42 (24.13)

0.261

32 (84.21)
104 (74.28)

6 (15.78)
36 (25.71)

0.201

21 (63.63)
115 (79.31)

12 (36.36)
30 (20.61)

0.056

9 (81.81)
127 (76.04)

2 (18.18)
40 (23.95)

0.662

104 (78.78)
32 (69.56)

28 (21.21)
14 (30.43)

0.205

No significant difference was found between the Survanta and Curosurf group.
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Table 7: Two-by-Two Comparison of the Effects of Survanta and Neosurf on Several
Variables among Neonates after Intervention
Type of surfactant
Variable
Pneumothorax
 Yes
 No
Patent ductus arteriosus
 Yes
 No
BPD
 Yes
 No
Intracranial haemorrhage
 Yes
 No
Pulmonary haemorrhage
 Yes
 No
Retinopathy
 Yes
 No
Ventilator therapy
 Yes
 No
NCPAP support
 Yes
 No
NCPAP support and
Ventilator therapy
 Yes
 No

Survanta

Neosurf

p Value

6 (100)
130 (93.52)

0
9 (6.47)

0.520

15 (93.75)
121 (93.79)

1 (6.25)
8 (6.20)

0.994

136 (93.79)

9 (6.20)

-

4 (100)
132 (93.61)

0
9 (6.38)

0.602

4 (100)
132 (93.61)

0
9 (6.38)

0.602

32 (91.42)
104 (94.54)

3 (8.57)
6 (5.45)

0.506

21 (100)
115 (92.74)

0
9 (7.25)

0.202

9 (75)
127 (95.48)

3 (25)
6 (4.51)

0.005

104 (94.54)
32 (91.42)

6 (5.45)
3 (8.57)

0.506

A statistically significant difference was found between Survanta and Neosurf group with a p
value of 0.005 for NCPAP support. This signifies that Neonates in the Neosurf group
required less NCPAP support. No significance was found between other variables.
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Table 8: Two-by-Two Comparison of the Effects of Curosurf and Neosurf on Several
Variables among Neonates after Intervention
Type of Surfactant
Variable
Pneumothorax
 Yes
 No
Patent ductus arteriosus
 Yes
 No
BPD
 Yes
 No
Intracranial haemorrhage
 Yes
 No
Pulmonary haemorrhage
 Yes
 No
Retinopathy
 Yes
 No
Ventilator therapy
 Yes
 No
NCPAP support
 Yes
 No
NCPAP support and
Ventilator therapy
 Yes
 No

Curosurf

Neosurf

p Value

42 (82.35)

9 (17.64)

-

3 (75)
39 (82.97)

1 (25)
8 (17.02)

42 (82.35)

9 (17.64)

-

42 (82.35)

9 (17.64)

-

42 (82.35)

9 (17.64)

-

6 (66.66)
36 (85.71)

3 (33.33)
6 (14.28)

0.174

12 (100)
30 (76.92)

0
9 (23.07)

0.06

2 (40)
40 (86.95)

3 (60)
6 (13.04)

0.009

28 (82.35)
14 (82.35)

6 (17.64)
3 (17.64)

1.000

0.688

A statistically significant difference was found between Curosurf and Neosurf group with a p
value of 0.005 for NCPAP support. This signifies that Neonates in the Curosurf group
required less NCPAP support. No significance was found between other variables.(Table 8)
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Table 9: Comparison of pre and post pH values of the Surfactants used in the treatment
of RDS
Survanta

P value

Curosurf

P value

Neosurf

pH

(mean±SD)

(mean±SD)

(mean±SD)

Pre

7±0.000

6.89±0.333

7.25±0.500

Post

7.03±0.174

7±0.000

7±0.000

0.325

0.347

p value

0.391

There were no significant changes in the pre and post pH values of the three surfactants.

Table 10: Comparison of pre and post pCO2 values of the Surfactants used in the
treatment of RDS
pCO2

Pre
Post

SURVANTA

P value

CUROSURF

P value

NEOSURF

(mean±SD)

(mean±SD)

(mean±SD)

52.33±15.793

49.56±11.282

54.50±18.628

41.30±10.853

0.003

30.89±8.268

0.002

41.50±13.723

p value

0.466

There was a statistically significant difference in pre and post values of pCO2 which is seen
in Survanta (p=0.003) and Curosurf (p=0.002) groups. (Table 10)

Table 11: Comparison of pre and post pO2 values of the Surfactants used in the
treatment of RDS
SURVANTA

p value

CUROSURF

p value

NEOSURF

pO2

(mean±SD)

(mean±SD)

(mean±SD)

Pre

51.45±37.340

45±28.325

40±29.292

Post

71.27±45.002

0.059

57±34.838

0.120

64.75±52.506

p value

0.492

There were no significant changes in the pre and post pO2 values of the three surfactants.
(Table 11)
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Table 12: Comparison of pre and post HCO3 values of the Surfactants used in the
treatment of RDS

HCO3

Survanta

p value

Curosurf

p value

Neosurf

(mean±SD)

(mean±SD)

(mean±SD)

Pre

18.75±7.844

12.80±6.380

21±2.646

Post

20.64±4.165

0.264

16.60±1.939

0.369

p value

20.33±3.512

0.868

There were no significant changes in the pre and post HCO3 values of the three
surfactants.(Table 12)

Table 13: Comparison of pre and post BE values of the Surfactants used in the
treatment of RDS

BE

SURVANTA
(mean±SD)

Pre

-7.31±4.222

Post

-4.58±4.300

p
value

CUROSURF
(mean±SD)

p
value

-11.50±3.937

0.007

-8.17±5.636

NEOSURF
(mean±SD)

p
value

-5.67±3.215

0.233

-7.00±3.464

0.739

There was a statistically significant difference in pre and post values of BE in the Survanta
group with a p value of 0.007. (Table 13)
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ASSESSING RISK FACTORS ASSOCIATED WITH RESPIRATORY DISTRESS
SYNDROME

Table 14:Severity of RDS with respect to mothers comorbidities during the gestation
period

VARIABLES

SEVERITY OF RDS N (%)
MILD
5 (7.35)

MODERATE
2 (5.12)

SEVERE
5 (9.09)

Upper Respiratory
Tract Infection

1 (1.47)

1 (2.56)

-

Hypertension

38 (55.88)

25 (64.1)

36 (65.45)

Hypothyroidism

10 (14.70)

6 (15.38)

6 (10.90)

Type 2 Diabetes Mellitus

1 (1.47)

1 (2.56)

3 (5.45)

Gestational Diabetes
Mellitus

4 (5.88)

2 (5.12)

1 (1.81)

Seizures

5 (7.35)

1 (2.56)

-

Convulsions

2 (2.94)

1 (2.56)

1 (1.81)

Anemia

-

-

1 (1.81)

Hyperthyroidism

2 (2.94)

-

1 (1.81)

Sepsis

-

-

1 (1.81)

Urinary Tract Infection

The frequencies of results depicted from the table above, it was ascertained that among
neonates diagnosed with mild rds the common comorbidities in mothers during that gestation
period included urinary tract infection 5 (7.35%), upper respiratory tract infection 1 (1.47%),
hypertension 38 (55.88%), hypothyroidism 10 (14.70%), type 2 diabetes mellitus 1 (1.47%),
gestational diabetes mellitus 4 (5.88%), seizures 5 (7.35%), convulsions 2 (2.94%) and
hyperthyroidism 2 (2.94 %).
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Among neonates that had moderate rds, the most common comorbidities among mothers
during that gestation period were urinary tract infection 2 (5.12%), upper respiratory tract
infection 1 (2.56%), hypertension 25 (64.1%), hypothyroidism 6 (15.38%), type 2 diabetes
mellitus 1 (2.56%), gestational diabetes mellitus 2 (5.12%), seizures 1 (2.56%) and
convulsions 1 (2.56%).
Among neonates that had severe rds, the most common comorbidities among mothers during
that gestation period were urinary tract infection 5 (9.09%), hypertension 36 (65.45%),
hypothyroidism 6 (10.90%), type 2 diabetes mellitus 3 (5.45%), gestational diabetes mellitus
1 (1.81%), convulsions 1 (1.81%), anemia 1 (1.81%), hyperthyroidism 1 (1.81%) and sepsis
1 (1.81%).

Table 15: Severity of RDS with respect to medications taken by the mother during the
gestation period

VARIABLES

SEVERITY OF RDS N (%)
MILD
174 (37.82)

MODERATE
115 (38.9)

SEVERE
102 (36.29)

Fe/Ca/Folic acid
prophylaxis

178 (38.69)

115 (38.9)

104 (37.01)

Neuroprophylaxis

5 (1.08)

3 (1.01)

8 (2.84)

Progesterone

9 (1.95)

6 (2.033)

6 (2.13)

Estrogen

1 (0.21)

1 (0.33)

2 (0.71)

Dydrogesterone

5 (1.08)

3 (1.01)

3 (1.06)

Iron

4 (0.86)

-

2 (0.71)

Nifedipine

5 (1.08)

1 (0.33)

3 (1.06)

Nicardipine

6 (1.30)

3 (1.01)

5 (1.77)

Methyldopa

6 (1.30)

6 (2.03)

5 (1.77)

TT Prophylaxis
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Table 15: Severity of RDS with respect to medications taken by the mother during the gestation
period
Labetalol

15 (3.26)

9 (3.05)

8 (2.84)

Alphadopa

3 (0.65)

-

4 (2.84)

Amlodipine

3 (0.65)

1 (0.33)

3 (1.06)

Aspirin

15 (3.26)

10 (3.38)

10 (3.55)

Ampicillin

1 (0.21)

-

-

Amoxicillin

-

-

1(0.35)

Levothyroxine

9 (1.95)

8 (2.71)

9(3.20)

Magnesium sulphate

7 (1.52)

5 (1.69)

2(0.711)

Metformin

7 (1.52)

4 (1.35)

1(0.35)

Insulin

7 (1.52)

5 (1.69)

3(1.06)

As depicted from the above table, neonates were grouped accordingly based on severity of
rds with respect to medications taken by the mother during the gestation period.
Among the neonates who had mild rds, following were the drugs taken during the gestation
period; tt prophylaxis 174 (37.82) , fe/ca/folic acid prophylaxis 178 (38.69%),
neuroprophylaxis 5 (1.08%), progesterone 9 (1.95%), estrogen 1 (0.21%), dydrogesterone 5
(1.08%), iron 4 (0.86%),

nifedipine 5 (1.08%), nicardipine 6 (1.30%), methyldopa 6

(1.30%), labetalol 15 (3.26%), alphadopa 3 (0.65%), amlodipine 3 (0.65%), aspirin 15
(3.26%), ampicillin 1 (0.21%), levothyroxine 9(1.95%), magnesium sulphate 7(1.52%),
metformin 7(1.52%) and insulin 7(1.52%).
Among the neonates who had moderate rds, following were the drugs taken during the
gestation period; tt prophylaxis 115 (38.9), fe/ca/folic acid prophylaxis 115 (38.9)
,neuroprophylaxis 3 (1.01), progesterone 6 (2.033), estrogen 1 (0.33), dydrogesterone 3
(1.01), nifedipine 1 (0.33) , nicardipine 3 (1.01) , methyldopa 6 (2.03), labetalol 9 (3.05) ,
amlodipine 1 (0.33), aspirin 10 (3.38), levothyroxine 8 (2.71) , magnesium sulphate 5 (1.69) ,
metformin 4 (1.35) and insulin 5 (1.69) .
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Among the neonates who had severe rds, following were the drugs taken during the gestation
period; tt prophylaxis 102 (36.29%), fe/ca/folic acid prophylaxis 104 (37.01%),
neuroprophylaxis 8 (2.84%), progesterone 6 (2.13%), estrogen 2 (0.71%), dydrogesterone 3
(1.06%), iron 2 (0.71%) nifedipine 3 (1.06%), nicardipine 5 (1.77%), methyldopa 5 (1.77%),
labetalol 8 (2.84%), alphadopa 4 (2.84%), amlodipine 3 (1.06%), aspirin 10 (3.55%),
amoxicillin 1(0.35%), levothyroxine 9 (3.20%), magnesium sulphate 2 (0.711%), metformin
1 (0.35%) and insulin 3 (1.06%). (table 15)

Table 16: Severity of RDS with respect to the APGAR score of the neonate
APGAR
SCORE
APGAR 1
MIN
(mean±SD)
APGAR 5
MIN
(mean±SD)

MILD
7.88±1.652

SEVERITY OF RDS
MODERATE
7.38±1.863

p Value
SEVERE
7.38±1.863

0.000

8.77±0.648

8.73±0.620

7.5±1.768

0.000

A p value of 0.000 was found for APGAR 1 minute which indicates that there is a significant
difference between the mild, moderate and severe groups. In mild RDS, the APGAR score
was found to be higher (7.88±1.652) than moderate RDS (7.38±1.863) and moderate RDS
had a higher score when compared with severe RDS (7.38±1.863).
A p value of 0.000 was found for APGAR 5 minute which indicates that there is a significant
difference between the mild, moderate and severe groups. In mild RDS, the APGAR score
was found to be higher (8.77±0.648) than moderate RDS (8.73±0.620) and moderate RDS
had a higher score when compared with severe RDS (7.5±1.768) (Table 16)
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Table 17: Severity of RDS with respect to Multiple pregnancy, Preterm rupture of
membrane and mode of delivery
VARIABLE

SEVERITY OF RDS N(%)
MILD

MODERATE

SEVERE

Multiple pregnancy

44 (43.13)

28 (27.45)

30 (29.41)

Preterm rupture of
membrane

45 (42.45)

30 (28.30)

31 (29.24)

42 (35.59)

34 (28.81)

42 (35.59)

196 (45.26)

122 (28.17)

115 (26.55)

Mode of delivery
 Vaginal


Caesarean

In association with severity of RDS with respect to mothers who have had

multiple

pregnancies, it was observed that (43.13%) neonates had mild RDS, (27.45%) neonates had
moderate RDS and (29.41%) neonates had diagnosed with severe RDS.
Among mothers who have had preterm rupture of membrane at the time of delivery, it was
found that (42.45%) neonates had mild RDS, (28.30%) neonates had moderate RDS and
(29.24%) neonates had severe RDS.
With respect to mode of delivery in relation with severity of RDS, it was seen that (35.59%)
neonates had mild RDS, (28.81%) of neonates had moderate RDS and (35.59%) neonates
were had severe RDS when the mother had delivered the baby vaginally. Among mothers
who underwent Caesarean, it was observed that (45.26%) neonates had mild RDS, (28.17%)
neonates had moderate RDS and (26.55%) of neonates had severe RDS.
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Table 18: Severity of RDS with respect to the Gestational age of the neonate

GESTATIONAL
AGE
≤32 weeks

SEVERITY OF RDS N (%)
MILD
MODERATE
SEVERE
88 (28.57)
91 (10.06)
129 (41.88)

p Value

0.000
>32 weeks

149 (63.13)

63 (26.69)

24 (10.16)

Among neonates with gestational age ≤32 weeks, it was found that 88 (28.57%) neonates had
mild RDS, 91 (10.06%) neonates had moderate RDS, and 129 (41.88%) neonates had severe
RDS. Among neonates with gestational age >32 weeks, it was observed that 149 (63.13%)
neonates had mild RDS, 63 (26.69%) neonates had moderate RDS and 24 (10.16%) neonates
were had severe RDS.(Table 18)

Table 19: Severity of RDS with respect to the gender of the neonate

GENDER

SEVERITY OF RDS N (%)
MILD

MODERATE

SEVERE

Male

138 (42.33)

92 (28.22)

96 (29.44)

Female

102 (44.34)

64 (27.82)

64 (27.82)

Among neonates of male gender, it was seen that 138 (42.33%) neonates had mild RDS, 92
(28.22%) neonates had moderate RDS and 96 (29.44%) neonates had severe RDS. Among
neonates of female gender, 102 (44.34%) neonates had mild RDS, 64 (27.82%) neonates had
moderate RDS and 64 (27.82%) neonates had severe RDS. (Table 19)
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TO EVALUATE RELATION OF RESPIRATORY DISTRESS SYNDROME WITH
OTHER COMORBID CONDITIONS.

Table 20: Severity of RDS with respect to comorbidities of the neonate
COMORBIDITIES

SEVERITY OF RDS N (%)

Perinatal asphyxia

MILD
-

MODERATE
2 (2.56)

SEVERE
11 (9.73)

Septic shock

1 (1.03)

2 (2.56)

7 (6.19)

Meconium Aspiration
Syndrome

-

-

1 (0.88)

Necrotizing Enterocolitis

3 (3.09)

2 (2.56)

4 (3.53)

Acidosis

-

1 (1.28)

5 (4.42)

Pneumonia

4 (4.12)

1 (1.28)

6 (5.30)

Meningitis

4 (4.12)

3 (3.84)

4 (3.53)

Anemia of prematurity

7 (7.21)

8 (10.25)

15 (13.27)

Apnea of prematurity

8 (8.24)

6 (7.69)

2 (1.76)

Neonatal
hyperbilirubinemia

45 (46.39)

24 (30.76)

18 (15.92)

Sepsis

25 (25.77)

29 (37.17)

40 (35.39)

The comorbidities associated in respiratory distress syndrome among neonates were
compared with respect to severity of rds. Among the neonates who were diagnosed with rds,
the most common comorbidities were found to be as follows;
Comorbidities among neonates diagnosed with mild rds were found to be septic shock 1
(1.03%), necrotizing enterocolitis 3 (3.09%), pneumonia 4 (4.12%), meningitis 4 (4.12%),
anemia

of prematurity 7

(7.21%),

apnea

of prematurity 8

hyperbilirubinemia 45 (46.39%) and sepsis 25 (25.77%).
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(8.24%),

neonatal

Comorbidities among neonates diagnosed with moderate rds were found to be perinatal
asphyxia 2 (2.56%), septic shock 2 (2.56%), necrotizing enterocolitis 2 (2.56%), acidosis 1
(1.28%), pneumonia 1 (1.28%), meningitis 3 (3.84%), anemia of prematurity 8 (10.25%),
apnea of prematurity 6 (7.69%), neonatal hyperbilirubinemia 24 (30.76%) and sepsis 29
(37.17%).
Comorbidities among neonates diagnosed with severe rds were found to be perinatal asphyxia
11 (9.73%), septic shock 7 (6.19%), meconium aspiration syndrome 1 (0.88%), necrotizing
enterocolitis 4 (3.53%), acidosis 5 (4.42%), pneumonia 6 (5.30%), meningitis 4 (3.53%),
anemia of prematurity 15 (13.27%), apnea of prematurity 2 (1.76%), neonatal
hyperbilirubinemia 18 (15.92%) and sepsis 40 (35.39%).(table 20)
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TO EVALUATE USE OF STEROIDS IN PREGNANT MOTHERS AND ITS
EFFECTS ON NEONATAL RESPIRATORY DISTRESS SYNDROME.

Table 21: Severity of RDS with respect to use of antenatal steroids
STEROID

SEVERITY OF RDS N (%)
MILD

MODERATE

SEVERE

Yes

111 (46.25)

56 (23.33)

73 (30.41)

No

42 (47.19)

23 (25.84)

24 (26.96)

With respect to use of antenatal steroids and severity of RDS as depicted from table 2, it was
revealed that when mothers were given with antenatal steroids, more number of neonates had
mild (46.25%) RDS and moderate (23.33%) RDS compared to severe RDS. Hence from this
study we can say that use of antenatal steroids can help reduce the severity of RDS in
neonates. (Table 21)
Table 22: Relation between use of antenatal steroids and death in neonates
STEROID

DEATH N (%)

P Value

Yes

No

Yes

16 (6.299)

238 (93.70)

No

17 (18.68)

74 (81.31)

0.001

With respect to understanding the relationship between use of antenatal steroids and
occurrence of death among neonates diagnosed with RDS; it was observed that 93.70%
neonates had improved after the mother had received antenatal steroids while only 81.31% of
neonates improved when no steroid was given. Mortality rate was found to be 6.299% in
neonates who received antenatal steroids whereas it was 18.68% in neonates who did not
receive antenatal steroids; this reveals that use of antenatal steroids reduced the mortality
among neonates diagnosed with RDS. (Table 22)
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Table 23: Relation between antenatal use of Dexamethasone and death
in neonates
Dexamethasone

DEATH N (%)
Yes

No

Yes

1 (3.12)

31 (96.87)

No

57 (9.87)

520 (90.12)

From the study, we could observe that when mothers had received antenatal Dexamethasone,
reduction of RDS was found to seen among 96.87% of neonates whereas 90.12% of neonates
improved when mothers did not receive dexamethasone. Mortality rate was found to be
3.12% when mothers received dexamethasone while mortality rate was found to be 9.87%
when mothers did not receive dexamethasone. (Table 23)

Table 24: Relation between antenatal use of Betamethasone and death in
neonates
Betamethasone

DEATH N (%)
Yes

No

Yes

1 (3.44)

28 (96.55)

No

57 (9.82)

523 (90.17)

From the study, we could observe that when mothers had received antenatal Betamethasone,
reduction of RDS was found to seen among 96.55% of neonates whereas 90.17% neonates
improved when mothers did not receive betamethasone. 3.44 % of neonates had been
succumbed to death when betamethasone was received by the mother while 9.82% of
neonates succumbed to death when mothers had not received betamethasone. (Table 24)
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DISCUSSION
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A retrospective study was carried out at Kasturba Hospital, Manipal in patients with RDS to
evaluate the use of surfactants in the treatment of RDS, assess the risk factors and
comorbidities associated with RDS and to evaluate the use of antenatal steroids and its effect
on RDS in neonates.

The mean gestational age of the study population was 31.80±3.161 week which was similar
to a study conducted by Mussavi M et al. where the mean gestational age was 31.6±3.7
weeks. (Mussavi, Mirnia and Asadollahi, 2016). In another study carried out by Bita Najafian
et al. the mean gestational age was 32.59±3.39 weeks. (Najafian et al., 2016).

The mean birth weight of the study population was found to be 1647.28±717.31 gram which
was similar to a study conducted by Mussavi M et al. where the mean birth weight was
1840±790 grams (Mussavi, Mirnia and Asadollahi, 2016). In another study carried out by
Bita Najafian et al. the mean birth weight was 1911.3±786.5 grams. (Najafian et al., 2016).

In our study the highest number of cases was found to be in males which were similar to
various studies conducted it was found that males were at an increased risk of RDS for all
gestational age while females were said be consistently at lower risk of RDS. (Anadkat et al.,
2012)(Melamed et al., 2009)(Yee,Amin and Wood,2008) (Dudell and Jain, 2006) According
to another study done by Rubaltelli et al. the male to female ratio of RDS affected infants was
found to be 1.3:1. Among the affected newborns, it was found that the case fatality rate
(CFR) for respiratory disorders was seen to be higher in males than in females. (Rubaltelli et
al., 1998).

We found that frequency of RDS was higher in extremely preterm (47.04%) and very preterm
(39.34%) neonates, this is in consistence with study performed by Ghartey et al.

who

concluded that infants delivered at early term had a two – fold increased risk of RDS, oxygen
use, CPAP use and composite respiratory morbidity. (Ghartey et al., 2012)
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Neonates with extremely low birth weight and very low birth weight had higher incidence of
RDS this was similar to the results of a study conducted by Fehlmann et al. which concluded
that incidence of RDS was more in preterm infants of very low birth weight..(Fehlmann et
al.,2010)

With regard to mode of delivery we found that incidence of RDS was higher in Caesarean
mode of delivery(77.04) this was in agreement with many studies that were carried out had
consistently shown that babies born by caesarean section were found to be at a higher risk of
developing RDS, this was because neonates born by caesarean section had larger residual
volume of lung fluid thereby less surfactant is secreted to the alveolar surface which delayed
the clearance of lung fluid .(Anadkat et al., 2012)(Sun et al.,2013)(Hansen et al., 2007)
(Ramachandrappa, A. and Jain, L., 2008) and according to Melamed et al. who found a two fold increased risk of RDS among neonates born by caesarean section. (Melamed et al.,
2009).

Our study showed that neonates whose mothers have had multiple pregnancies were at the
risk of developing RDS. This result was in consistence with study conducted by Sun et al.
which concluded that in both preterm and term infants, multiple gestations were associated
with increased risk of RDS. (Sun et al., 2013)

There was an increased risk of developing RDS when the mother was had PROM this was in
consistence with the study conducted by Jahromi et al. in which it was found that out of 94
neonates who had preterm rupture of membrane less than 12 hours, 41 cases (43.6%) had
developed RDS. Duration of rupture of the membrane among 19 neonates was found to be
between 12 and 24h among which 6 of them (31.6%) had developed RDS. In 21 cases whose
rupture of the membrane was found to be between 24 to 48 h, RDS was seen among 4 (19%)
cases and therefore it was concluded that increase in the duration of preterm rupture of the
membrane in the first 48 hours decreased the risk of RDS with a linear pattern. (Namavar
Jahromi, Ardekany and Poorarian, 2000).

Our study concluded that mothers who had preeclampsia and diabetes during gestation led to
an increased risk of neonates developing RDS which was reciprocal to the study conducted
by Pugni et al. in which it was found that all infants small for gestational age prematurely
born from preeclamptic women, appeared to be a high risk group for adverse respiratory
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outcome (Pugni et al.,1999) and according to the study conducted by Piper et al. it was
concluded that pregnancies in which maternal glucose levels were found to be poorly
controlled, there was an association with delayed appearance of biochemical indicators of
pulmonary maturity such a phosphatidylglycerol.(Piper, Xenakis and Langer, 1998).
Various complications of prematurity were elated to RDS such as pneumothorax, retinopathy,
patent ductus arteriosus, BPD, intracranial hemorrhage and pulmonary hemorrhage which
was similar to the result of a study done by Agrons et al. various complications of
prematurity such as intracranial hemorrhage, necrotizing enterocolitis, sepsis, patent ductus
arteriosus, retinopathy of prematurity, pulmonary hemorrhage, pneumonia, pneumothorax
and BPD that were related to RDS were assessed out of which pulmonary hemorrhage,
pneumonia, pneumothorax and BPD were found to be the most common cause of neonatal
morbidity. (Agrons et al., 2005).

The use of antental steroid is associated with reduced severity of RDS and morbidity of the
neonate. This factor is discussed later in this section.
NCPAP was used in neonates who had mild or moderate RDS. As per the European
Consensus Guidelines for 2013, it was recommended that non - invasive respiratory support
should be used at birth for all infants who are at risk for RDS. .(Sweet et al.,2013)
(Mahmoud, Roehr and Schmalisch, 2011). A systematic review from Cochrane collaboration
showed that use of CPAP in preterm infants with RDS significantly reduced treatment failure.
In addition, a reduction in the need for additional mechanical ventilation was observed. (Ho,
Henderson – Smart and Davis,2002). CPAP use was found to reduce the mortality among
preterm with RDS. Neonates at higher risk of RDS/ severe RDS were given ventilator
therapy which was in consistence with the study conducted by Morley et al. which revealed
revealed that Non – invasive ventilation could not always provide effective oxygenation and
stable the lung mechanics. Therefore mechanical ventilation remained an essential technique
to care for preterm infants with RDS for whom non – invasive ventilation failed. (Morley et
al., 2008). Mortality of RDS was found to be 9.50%.

When the general characteristics of the patient were compared before intervention a
significant difference of p=0.017 was found with respect to gestational age which signified
the use of surfactants was more in less than equal to 32 weeks group which was in
accordance with a study conducted by Condo et al. the frequency of RDS decreased with
increasing gestational age therefore, reducing the need for surfactant (Condo et al., 2016) and
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with another study conducted by Enezi et al. majority of subjects were premature and
underwent surfactant replacement therapy (A. Enezi et al., 2018).

A significant difference of p=0.012 was found with respect to birth weight which signified
use of surfactants was more in <1,500 g group which was in consistence with a study
conducted by Fehlmann et al. which revealed that use of surfactant and supportive therapy
was more in preterm infants of very low birth weight. (Fehlmann et al., 2010). As per
another study conducted by Enezi et al. one of the reasons for neonates undergoing surfactant
therapy was low birth weight besides other factors like prematurity, transient tachypnea and
respiratory failure. (A. Enezi et al., 2018).

A significant p value of 0.026 was found for pulmonary hemorrhage between the groups with
number of neonates being more in survanta group.
When the general characteristics of the patient were compared after intervention in ≤32
weeks group a significant difference of p=0.010 was found with respect to NCPAP which
signified that Curosurf group required least support it was in consistence with a study
conducted by Ramanathan et al., in which effectiveness of Curosurf and Survanta was
compared and it was found that a significantly lower oxygen demand was seen in curosurf
group. (Ramanathan et al., 2004).

According

to

another

study

conducted

by

Bita

Nafajian

et

and safety of Survanta and Curosurf were compared it was found that

al.,

efficacy

prescription of

Curosurf was associated with lower CPAP or endotracheal tube requirement. (Nafajian et al.,
2016).
As per a review article by Corff et al. the institutes were keen on extubating neonates post
surfactant. A surfactant which is rapid acting and easy to administer can reduce the time to
extubation to CPAP. (Corff et al., 2006).

General characteristsics of the neonates could not be compared in the >32 weeks group as
only survanta was used.
When a two-by-two comparison of surfactants was done no significant difference was found
between Survanta and Curosurf.
Between a two-by-two comparison of surfactants there was significant difference between
Survanta and Neosurf group with a p value of 0.005 for NCPAP support. This signifies that
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Neonates in the Neosurf group required less NCPAP support. No significance was found
between other variables.
Between a two-by-two comparison of surfactants there was significant difference between
Survanta and Neosurf group with a p value of 0.005 for NCPAP support. This signifies that
Neonates in the Neosurf group required less NCPAP support. No significance was found
between other variables.

But, when Neosurf and Curosurf were compared statistically significant difference was found
between Curosurf and Neosurf group with a p value of 0.005 for NCPAP support. This
signifies that neonates in the Curosurf group required less NCPAP support. No significance
was found between other variables. Ad discussed earlier Curosurf required less oxygenation
support.

Significant differences were found between pre and post values of Pco2. There was a
statistically significant difference in pre and post values of pCO2 which is seen in the
Survanta group(p=0.003) and Curosurf group(p=0.002). According to study conducted by
Proquitte et al. the PCO2 values had significantly decreased after Curosurf administration.
(Proquitte et al., 2007). According to a study conducted by Enezi et al. there was significant
difference in pre-surfactant and post-surfactant values of Pco2 at p=0.001 (A. Enezi et
al.,2018).

There was a statistically significant difference in pre and post values of BE in the Survanta
group with a p value of 0.007. According to a study conducted by Enezi et al. there was
statistical significance in pre and post base excess. (A. Enezi et al.,2018).

Severity of RDS among neonates with respect to comorbidities of the mother during the
gestation period were grouped accordingly. As per a similar study conducted by Obladen, it
was concluded that a retardation of pulmonary maturity was found to be seen in infants with
maternal diabetes and maternal hypothyroidism. (Obladen, 1978). As discussed earlier
hypertension and diabetes was found to show a major role in increasing the severity of RDS.

Among the neonates who had mild rds, following were the drugs taken by the mothers during
the gestation periods; tt prophylaxis (37.82), fe/ca/folic acid prophylaxis (38.69%), labetalol
(3.26%) and aspirin (3.26%). Among the neonates who had moderate rds, following were the
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drugs taken by the mothers during the gestation periods; tt prophylaxis (38.9), fe/ca/folic acid
prophylaxis (38.9), labetalol (3.05), aspirin (3.38) and levothyroxine (2.71) among the
neonates who had severe rds, following were the drugs taken by the mothers during the
gestation periods; tt prophylaxis (36.29%), fe/ca/folic acid prophylaxis (37.01%),
neuroprophylaxis (2.84%), labetalol (2.84%), alphadopa

(2.84%), aspirin

(3.55%) and

levothyroxine (3.20%).

A p value of 0.000 was found for APGAR 1 minute which indicates that there is a significant
difference between the mild, moderate and severe groups. In mild RDS, the APGAR score
was found to be higher (7.88±1.652) than moderate RDS (7.38±1.863) and moderate RDS
had a higher score when compared with severe RDS (7.38±1.863). A p value of 0.000 was
found for APGAR 5 minute which indicates that there is a significant difference between the
mild, moderate and severe groups. In mild RDS, the APGAR score was found to be higher
(8.77±0.648) than moderate RDS (8.73±0.620) and moderate RDS had a higher score when
compared with severe RDS (7.5±1.768). In consistence with a study conducted by Chambliss
and Bay, a 5 minute APGAR score of 7 or less was found to be an independent risk factor for
RDS and therefore were very likely to develop RDS. (Chambliss and Bay, 2005).
Among neonates with gestational age ≤32 weeks, it was found that 88 (28.57%) neonates had
mild RDS, 91 (10.06%) neonates had moderate RDS, and 129 (41.88%) neonates had severe
RDS. Among neonates with gestational age >32 weeks, it was observed that 149 (63.13%)
neonates had mild RDS, 63 (26.69%) neonates had moderate RDS and 24 (10.16%) neonates
had severe RDS.

Among neonates of male gender, it was seen that 138 (42.33%) neonates had mild RDS, 92
(28.22%) neonates had moderate RDS and 96 (29.44%) neonates had severe RDS. Among
neonates of female gender, 102 (44.34%) neonates had mild RDS, 64 (27.82%) neonates had
moderate RDS and 64 (27.82%) neonates were found have severe RDS.

Comorbidities among neonates diagnosed with mild rds were found to be septic shock 1.03%,
necrotizing enterocolitis 3.09%, pneumonia 4.12%, meningitis 4.12%, anemia of prematurity
7.21%, apnea of prematurity 8.24%, neonatal hyperbilirubinemia 46.39% and sepsis 25.77%.
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Comorbidities among neonates diagnosed with moderate rds were found to be perinatal
asphyxia 2.56%, septic shock 2.56%, necrotizing enterocolitis 2.56%, acidosis 1.28%,
pneumonia 1.28%, meningitis 3.84%, anemia of prematurity 10.25%, apnea of prematurity
7.69%, neonatal hyperbilirubinemia 30.76% and sepsis 37.17%.

Comorbidities among neonates diagnosed with severe rds were found to be perinatal asphyxia
9.73%, septic shock 6.19%, meconium aspiration syndrome 0.88%, necrotizing enterocolitis
3.53%, acidosis 4.42% , pneumonia 5.30% , meningitis 3.53% , anemia of prematurity
13.27%, apnea of prematurity 1.76%, neonatal hyperbilirubinemia 15.92% and sepsis
35.39%.

It was revealed that when mothers were given with antenatal steroids, more number of
neonates had mild (46.25%) RDS and moderate (23.33%) RDS in comparison with severe
RDS. Hence from our study we can conclude that use of antenatal steroids can help reduce
the severity of RDS in neonates. According to a study conducted by Heljic et al. it was
concluded that antenatal corticosteroid administration significantly reduced the incidence and
severity of RDS in premature neonates. It is recommended to initiate antenatal corticosteroid
therapy among women between 24 and 34 weeks of gestation as early as preterm delivery
appears to be likely. (Heljic et al.,2009). According to studies conducted by Crowley P.,
Wright et al. and Chien. it was concluded that antenatal steroids significantly reduced the
mortality among neonates with respiratory distress syndrome. Among infants born at or
earlier than 27 weeks gestation, the incidence of Respiratory distress syndrome was not found
to be reduced after exposure to antenatal steroids although the severity seemed to be lower.
(Crowley, 2006) (Chien, 2002) (Wright et al., 1995).
With respect to understanding the relationship between use of antenatal steroids and
occurrence of death among neonates diagnosed with RDS; it was observed that 93.70%
neonates had improved after the mother had received antenatal steroids while only 81.31% of
neonates improved when no steroid was given. Mortality rate was found to be 6.29% in
neonates who received antenatal steroids whereas it was 18.68% in neonates who did not
receive antenatal steroids; this reveals that use of antenatal steroids reduced the mortality
among neonates diagnosed with RDS. According to a study conducted by Shahzad et al.
Initiation of antenatal steroid treatment has evolved as the most effective treatment for
reducing early neonatal morbidity and mortality among women who are at risk of preterm
delivery. (Shahzad F., Umar N., 2016).
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LIMITATIONS
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The general limitations for any retrospective study applies to our study as well.


The paper on which the ABG values were printed fades over time and hence we could
not collect ABG values for all patients.



The number of patients who received Neosurf were very less when compared to
Survanta and Curosurf.
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CONCLUSION
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This is the first retrospective study in South India conducted to compare the efficacy of three
naturally occurring surfactants Survanta,Curosurf and Neosurf.
Demographics of 610 neonates with RDS showed that incidence of RDS is greater in males,
the risk of RDS decreases with increasing gestational age and birth weight. The incidence of
RDS increases with caesarean delivery and PROM, preeclampsia, IDM.

Among 610 neonates diagnosed with RDS, 191 received surfactant therapy. These neonates
were then grouped based on the gestational age groups less than equal to 32 weeks and more
than 32 weeks, two-by-two comparison of surfactants and ABG values pre and post
surfactant it was concluded that neonates in less than or equal to 32 weeks of gestational age
required surfactant therapy more than neonates in more than 32 weeks group, in less neonates
in Curosurf group required lesser NCPAP support as compared to Survanta and Neosurf and
there was a significant reduction in pCo2 values after surfactant administration, Survanta and
Curosurf both showed significance.

Risk factors associated with RDS in neonates were assessed with respect to severity of RDS.
It was found out that neonates whose mothers were having hypertension, type 2 diabetes
mellitus, gestational diabetes and hypothyroidism during gestation were at higher risk of
RDS. Mothers medications also could have affected the neonates risk of developing RDS.
Factors such as gestational age of the neonate and 1 minute APGAR and 5 minute APGAR
were found to be significant factors contributing in increasing the risk of RDS. Neonates
comorbidities were studied and their relation with RDS severity was assessed.

Use of antental steroids significantly reduced the number of deaths and also reduced the
severity of RDS.
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